What is Erste Group Bank's Estimate for NVO FY2026 Earnings?

Key Points

• Erste Group Bank cut its FY2026 EPS estimate for Novo Nordisk to $3.23 from $3.27, which is still below the broader analyst consensus of $3.41 per share.
• Despite the lower estimate, analyst sentiment remains mixed but mostly cautious: MarketBeat says Novo Nordisk has a Hold consensus rating, with five Buy ratings, seventeen Hold ratings, and one Sell rating.
• The stock rose 1.6% in Thursday trading to $48.69, while recent developments such as temporary Medicare coverage for GLP-1 obesity drugs and a manufacturing partnership in India could support future demand.

Novo Nordisk A/S (NYSE:NVO - Free Report) - Erste Group Bank lowered their FY2026 earnings estimates for Novo Nordisk A/S in a research note issued on Thursday, June 25th. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings per share of $3.23 for the year, down from their prior forecast of $3.27. The consensus estimate for Novo Nordisk A/S's current full-year earnings is $3.41 per share.

Other equities analysts have also recently issued reports about the stock. Zacks Research raised shares of Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, March 10th. Wolfe Research started coverage on Novo Nordisk A/S in a research note on Thursday, March 26th. They set a "peer perform" rating on the stock. Sanford C. Bernstein started coverage on Novo Nordisk A/S in a research note on Wednesday, March 18th. They issued an "outperform" rating and a $175.00 price objective for the company. TD Cowen cut Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $42.00 price objective for the company. in a report on Tuesday, March 10th. Finally, Nordea Equity Research raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Friday, June 19th. Five investment analysts have rated the stock with a Buy rating, seventeen have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $65.56.

Novo Nordisk A/S Trading Up 1.6%

NYSE:NVO opened at $48.69 on Thursday. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $71.79. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. The stock has a fifty day moving average price of $44.25 and a two-hundred day moving average price of $45.81. The stock has a market capitalization of $217.40 billion, a price-to-earnings ratio of 11.43, a PEG ratio of 4.33 and a beta of 0.77.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The business had revenue of $10.85 billion during the quarter.

Institutional Trading of Novo Nordisk A/S

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Smith Chas P & Associates PA Cpas grew its holdings in Novo Nordisk A/S by 105.3% in the 3rd quarter. Smith Chas P & Associates PA Cpas now owns 405,425 shares of the company's stock valued at $22,497,000 after buying an additional 207,959 shares during the period. CIBC Bancorp USA Inc. purchased a new stake in Novo Nordisk A/S during the third quarter worth approximately $19,519,000. Romano Brothers AND Company increased its position in shares of Novo Nordisk A/S by 704.0% in the fourth quarter. Romano Brothers AND Company now owns 34,236 shares of the company's stock worth $1,742,000 after acquiring an additional 29,978 shares in the last quarter. Capital Investment Counsel LLC purchased a new position in shares of Novo Nordisk A/S in the 4th quarter valued at $3,727,000. Finally, Marathon Capital Management lifted its holdings in shares of Novo Nordisk A/S by 43.9% during the 4th quarter. Marathon Capital Management now owns 82,705 shares of the company's stock valued at $4,208,000 after acquiring an additional 25,230 shares in the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Medicare is starting temporary coverage for GLP-1 obesity treatments, including Novo Nordisk’s Wegovy injection and tablet, which could broaden access and increase demand for the company’s weight-loss drugs. Medicare will start covering obesity drugs for the first time. Here's what patients should know
• Positive Sentiment: Shantha Biologics announced an outsourcing agreement with Novo Nordisk to provide cartridge fill-finish manufacturing services in India, a move that could help strengthen supply and support future product demand. Shantha Biologics Announces Cartridge Fill-Finish Collaboration
• Positive Sentiment: Nordea upgraded Novo Nordisk to Buy, signaling improved analyst confidence in the stock’s valuation and dividend appeal. Novo Nordisk (NVO) Upgraded to Buy at Nordea. Here is Why
• Positive Sentiment: Shares also rose after the company was highlighted as outperforming the broader market in recent trading, reflecting investor appetite for the name amid obesity-drug optimism. Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note
• Neutral Sentiment: News coverage around weight-loss ETFs and broader obesity-treatment investing reinforces sector interest, but it is more of a thematic tailwind than a direct catalyst for Novo Nordisk. Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage
• Neutral Sentiment: Erste Group trimmed its FY2027 EPS estimate slightly, which is a modest cautionary note, though it did not change the broader longer-term growth story. Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.